全球急性肌張力不全症市場按藥物類別、年齡層、分銷管道和地區分類

2025 年全球急性肌張力不全症市場規模估計為 1.208 億美元，預計到 2032 年將達到 1.526 億美元，2025 年至 2032 年的複合年成長率為 3.4%。

數字。 2025年全球市場佔有率急性肌張力不全症市場各地區佔有率（%）

急性肌張力不全症是一種運動障礙，其特徵是導致重複運動和異常姿勢的不自主肌肉收縮。這些收縮可能會很痛苦，通常是由突然的肌肉痙攣引起的。急性肌張力不全症可影響身體的任何部位，包括頸部（頸部肌肌張力不全症）、眼睛（眼部肌肌張力不全症）、下顎或舌頭或四肢。這種症狀可能有多種原因，包括：

• 藥物引起的肌張力不全症：這是最常見的原因之一。它可能是某些藥物的副作用，特別是抗精神病藥物，會影響大腦中的多巴胺路徑。
• 特發性肌張力不全症：病因不明。
• 次發性肌張力不全症：由威爾森氏症、亨丁頓舞蹈症、巴金森氏症、腦損傷或中風等潛在疾病所引起。

市場動態

全球急性肌肌張力不全症市場的發展受到引發急性肌肌張力不全症失調的神經系統疾病（如帕金森氏症、腦性麻痹和遲發性）盛行率上升的推動。例如，根據世界衛生組織（WHO）2024年8月9日發布的報告，巴金森氏症（PD）是一種導致運動、心理健康、睡眠、疼痛和其他健康問題的腦部疾病。 2021年，美國有近100萬人患有帕金森氏症（PD），預計到2030年這數字將增加至120萬人。帕金森氏症是繼阿茲海默症之後第二常見的神經退化性疾病。

此外，根據美國生物技術資訊中心2022年3月發布的報告，美國每年每1,000名幼兒中就有2.3至3.6名患有腦性麻痹。痙攣型腦性麻痹是最常見的類型，佔所有腦性麻痹的61%至76.9%。

研究的主要特點

• 本報告對全球急性肌張力不全症市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率(CAGR)。
• 它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
• 它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數，介紹了全球急性肌肌張力不全症市場的主要企業概況。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
• 全球急性肌張力不全症市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
• 相關人員將透過全球急性肌肌張力不全症市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 肌張力不全症不斷上升
  • 藥物相關副作用
  • 了解不斷變化的治療模式
• 監管指南
• 市場趨勢
• PEST分析
• 投資與資金籌措
• 合併、收購和合作
• 產品映射
• 識別頂級市場參與企業
• 市場參與企業採取各種業務發展策略
• 國家醫療費用支出

4. 全球急性肌張力不全症市場-冠狀病毒（COVID-19）大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 2020 年至 2032 年全球急性肌張力不全症市場（依藥物類別）

• 介紹
• 抗膽鹼藥物
• 苯二氮平類藥物
• 其他（神經毒素等）

6. 全球急性肌張力不全症市場（依年齡層分類），2020 年至 2032 年

• 介紹
• 嬰兒
• 成人

7. 2020 年至 2032 年全球急性肌張力不全症市場（依通路分類）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 全球急性肌張力不全症市場（按地區），2020 年至 2032 年

• 介紹
• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東
• 非洲

第9章 競爭態勢

• 公司簡介
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • SSPharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

第 10 章 章節

• 參考
• 調查方法
• 關於出版商

Global Acute Dystonia Market is estimated to be valued at USD 120.8 Mn in 2025 and is expected to reach USD 152.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.4% from 2025 to 2032.

Figure. Global Acute Dystonia Market Share (%), By Region 2025

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

• Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
• Idiopathic Dystonia: Where the cause is unknown
• Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2024, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

• Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
• Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
• Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Age Group
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of dystonia
  • Side effects associated with drugs
  • Understanding changing treatment patterns
• Key Highlights
• Regulatory Guidelines
• Market Trends
• PEST Analysis
• Investments and Funding
• Mergers, Acquisitions, and Collaborations
• Product Mapping
• Identification of Top Market Players
• Adoption of Various Business Development Strategies by the Market players
• Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Anticholinergic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Neurotoxin, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Fresenius Kabi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
• Analyst Views

10. Section

• References
• Research Methodology
• About us